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Abstract Cardiovascular disease (CVD) is a pre-
ventable disease, which combines two general processes:
chronic vascular inflammation and acute thrombosis. Both
are amplified with positive feedback signals by n-6 eico-
sanoids derived from food-based n-6 highly unsaturated
fatty acids (n-6 HUFA). This amplification is lessened by
competing actions of n-3 HUFA. Death results from fatal
interactions of the vascular wall with platelets and clotting
proteins. The benefits of fish oil interventions are con-
founded by complex details in pharmacokinetics, pharma-
codynamics, adverse events, timescale factors, topology,
financial incentives and people’s sense of cause and effect.
Two basic aspects of n-3 HUFA that are overlooked in
CVD dynamics are saturable, hyperbolic responses of the
enzymes continually supplying n-6 HUFA and hard-to-
control positive feedback receptor signals by excessive n-6
HUFA–based mediators. Multiple feedback loops in
inflammation and thrombosis have diverse mediators, and
reducing one mediator that occurs above its rate-limiting
levels may not reduce the pathophysiology. Clinicians have
developed some successful interventions that decrease
CVD deaths in the form of secondary prevention. However,
the current high CVD prevalence in the USA remains
unchanged, and successful primary prevention of CVD
remains uncertain. This review weighs the available evi-
dence to help clinicians, the biomedical community and the
public put the use of fish oil supplements into a balanced
perspective.
Key Points
The hyperbolic dynamics of enzyme-catalysed
processes and the hard-to-control, explosive nature
of positive feedback signals are often overlooked in
the design and interpretation of cardiovascular
disease (CVD) interventions.
Among apparently normal human populations with
different ethnic food habits, the highly unsaturated
fatty acid (HUFA) balance (% n-6 in HUFA) in
blood lipids ranges from 25 % n-6 in HUFA to 85 %
n-6 in HUFA.
The % n-6 in HUFA in blood lipids relates directly to
the omega 3–6 balance of the foods ingested and
also to the intensity of the resulting n-6 eicosanoid–
related chronic health disorders.
In the absence of n-3 nutrients, the essential dietary
nutrient n-6 linoleic acid has a very narrow
therapeutic window between efficacy and harm,
which is widened by n-3 HUFA in fish oil
supplements.
Dietary fish oil could be a successful supplement in
primary preventive interventions in CVD that
balance the intakes of n-3 and n-6 nutrients and
maintain balanced n-3 and n-6 HUFA in tissues.
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1 Introduction
Assessing the benefits and risks of fish oil supplements in
reducing harm from cardiovascular disease (CVD)
addresses an urgent need to understand effective ways to
prevent ill-informed food choices from causing sickness
and death. The US Centers for Disease Control and
Prevention (CDC) describes CVD as a preventable disease
[1], while its prevalence continues little diminished [2]. A
growing interest in using fish oil to prevent CVD is seen in
the US National Library of Medicine PubMed database,
which lists over 4500 scientific reports from 1960 to the
present (Fig. 1). While abundant data on efficacy and
adverse effects exist, their orderly assembly has not yet
provided broad agreement on an effective way to handle
this approach to CVD. The lack of success is due in part to
cursory handling of the connected molecular actions that
mediate pharmacokinetics, pharmacodynamics, adverse
events, timescale factors, financial incentives and people’s
sense of cause and effect. These combine to burden sta-
tistical rigour and logic, tempting people into hasty con-
clusions about benefit and risk.
Perseverance and rigorous logic are needed to integrate
the many CVD concepts into multi-compartment models
that correctly represent the complex reality that occurs
when a person ingests n-3 and n-6 nutrients. Oversimplified
mono-compartment and two-compartment models are often
used to interpret clinical trials of patented medications.
However, the complexity is much greater for n-3 nutrient
actions than for most medications. Dietary essential n-3
fatty acids act continually in the presence of abundant
competing n-6 homologues, and both n-3 and n-6 highly
unsaturated fatty acids (HUFA) form important bioactive
mediators. This review weighs the available evidence to
help clinicians, the biomedical community and the public
put the use of fish oils into a balanced perspective.
2 Balancing Three Aspects: Risk, Benefit and Dose
2.1 Risk and Surrogate End Points
The current risk of CVD among Americans is great. The
National Heart, Lung, and Blood Institute (NHLBI) has
noted that two thirds of Americans over 60 years of age
have CVD, and it killed 788,000 in 2010 (see pages 33, 41
and 47 in Ref. [2]). The need for interventions that lower
the risk is obvious. However, 788,000 deaths each year
mean that only about 25 per 10,000 Americans die of CVD,
while 9975 do not. This makes the statistics of primary
prevention a difficult challenge. Clinicians would need to
intervene consistently with thousands of people for many
years to see significant primary prevention of CVD deaths.
To design more statistical power, CVD trials often monitor
surrogate end points that occur sooner and with more fre-
quency than death. They also recruit individuals already
likely to have preclinical CVD, making trials more like
secondary than primary interventions.
Biomarkers consistently predicting the risk of fatal CVD
events are often used hopefully as a surrogate end point.
Assessment of risk depends on the end point being a valid
surrogate for CVD death, i.e. causally connected to CVD
death. However, some predictive biomarkers are comor-
bidities that result from a common underlying process.
They are only associated factors with no direct causal role
in CVD. In reviewing the limited success of several large
and expensive CVD trials, the NHLBI director noted in
1987 that ‘‘There is no question that surrogate end points
are a big issue’’ [3]. Large clinical trials using comorbid
conditions and biomarkers that strongly predict the risk of
CVD have lowered the presumed surrogates without sig-
nificantly lowering CVD death rates. Such trials have
included lowering obesity without reducing the CVD event
rate [4]; lowering blood cholesterol with dietary n-6 lino-
leic acid (LA; 18:2n-6) but increasing the CVD death rate
[5]; and intensive control of blood glucose in type 2 dia-
betic patients but an increased CVD death rate [6]. These
interventions changed biomarkers but did not prevent the
path to CVD.
With regard to CVD and fish oil supplements, many
physicians seem uninformed about the physiological roles
and amounts of n-3 and n-6 nutrients in foods. Analysis of
17 randomized, controlled cardiovascular clinical trials
showed a disappointing risk ratio (RR) of 0.97 for ‘diet
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Fig. 1 Scientific reports on fish oil and cardiovascular disease. A
search of PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) for ‘fish
oil cardiovascular disease’ in January 2016 retrieved 4585 reports
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evident for using n-3 supplements, with an RR of 0.77 [7].
Hindsight suggests that successful CVD clinical trials will
use surrogate biomarkers that are within the chain of
molecular actions connecting food habits to death. The n-3
HUFA in fish oils operate in such pathways, and the HUFA
balance (% n-6 in HUFA) is a valid biomarker for the
outcomes of those pathways.
Inflammation and thrombosis in CVD are amplified by
positive feedback signals from food-based n-6 mediators
[8]. Ecological observations have suggested primary pre-
ventive interventions that might succeed. For example, an
unintended beneficial intervention showed a food-based
origin for CVD when the lower rate of CVD in Europe
during the Second World War reversed afterwards (re-
viewed in Ref. [9]). An unintendedly harmful intervention
resulted in higher rates of CVD in Japanese migrants in
Brazil who ate less fish and had lower n-3 HUFA levels in
plasma phospholipids [10].
Similar differences occurred with Japanese migrants in
Minnesota who adopted new food habits [11]. Different
intakes of n-3 and n-6 nutrients (rather than genetic dif-
ferences) gave HUFA balances of 37 % n-6 in HUFA for
rural Japanese, 44 % for urban Japanese, 74 % for Japa-
nese Americans and 81 % for Caucasian Americans [11].
Heart attacks were much less frequent among traditional
Japanese (with about 35 % n-6 in HUFA) and Inuits (with
about 25 % n-6 in HUFA) eating large amounts of marine
foods rich in n-3 HUFA [9]. People maintaining[50 % n-6
in HUFA throughout their lifetime clearly have a greater
risk of CVD death than people with\50 % n-6 in HUFA
[12, 13]. Clinical trials have not yet examined clinical
outcomes from long-term HUFA balances near 50 % n-6 in
HUFA.
2.2 Benefit and Comorbidities
The benefit of not dying and of reducing a cause of dying
seems obvious (though hard to quantitate), whereas benefit
from reducing an associated predictive biomarker requires
caution. Reducing a non-causal biomarker may give little
benefit in reducing CVD death [4–6]. On the other hand,
when comorbidities are caused by a common underlying
process, reducing that process may give many more ben-
efits than expected. Too narrow a focus on one disease can
neglect important benefits. Figure 2 notes many chronic
health conditions that are made worse by excessive actions
of n-6 HUFA–based products of the arachidonic acid cas-
cade [8, 14]. The use of fish oil supplements to balance n-3
and n-6 HUFA precursors beneficially diminishes inflam-
mation and thrombosis plus many other comorbidities
(Fig. 2). Such pleiotropy is seldom encountered (and often
ignored) in drug efficacy trials, for which limited benefits
are more easily assessed.
Occupational medicine experts have identified dozens of
chronic health conditions other than CVD that cause major
health-related financial losses for US corporations [15, 16].
Many of these conditions (see Table 1 in Ref. [8]) are
made worse by excessive n-6 actions, and the HUFA bal-
ance is linked to financial loss (see Fig. 2 in Ref. [14]). The
balance of n-3 and n-6 HUFA in blood lipids [17] is a
valuable surrogate for monitoring food-based interven-
tions. Ironically, CVD (the top cause of death) is not
among the top ten conditions causing health-related
financial losses (see Fig. 1 in Ref. [15]), and many other
food-based health conditions with excessive actions of n-6
eicosanoids [16, 18] cause the top ten financial losses [15].
Interventions with fish oil that lower the HUFA balance
and the prevalence of CVD and n-6-mediated comorbid
conditions will likely give large overall benefits measured
in terms of lower health-related financial losses and a
greater sense of wellbeing [14, 16, 18].
2.3 Dose and Therapeutic Windows
Clinical trials are often designed to assess actions of
patented drugs that are not found in humans. Pharma-
cokinetic and pharmacodynamic actions often occur in
minutes or hours as drugs are metabolized and excreted,
and most adverse effects are recognized quickly. Increased
doses give increased benefits until undesired events
become evident at higher doses. This occurs with anti-
inflammatory and anti-thrombotic drugs [19, 20]. When the
therapeutic window is narrow, prudent practice uses the
beneficial drug at its lowest effective dose and monitors its
levels continually to avoid adverse events [21].
To illustrate complex CVD-related conditions in which
actions of fish oil supplements can be evaluated, this article
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Fig. 2 Health conditions linked to the highly unsaturated fatty acid
(HUFA) balance. ADHD attention deficit–hyperactivity disorder,
COPD chronic obstructive pulmonary disease, GERD gastroe-
sophageal reflux disease, PTSD post-traumatic stress disorder
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notes some pharmacokinetic and pharmacodynamic actions
of aspirin on CVD processes. Both aspirin and fish oil are
rapidly absorbed and rapidly removed (aspirin by hydrol-
ysis and fish oil by incorporation into tissue phospholipids).
Both give pleiotropic benefits by slowing the arachidonic
acid cascade pathway [8] and decreasing harmful positive
feedback signals by n-6 eicosanoids. A major difference in
action is that aspirin rapidly and irreversibly inhibits the
cyclooxygenase that forms n-6 eicosanoids in the patho-
physiological chain of events, and it has a narrow thera-
peutic window above which many serious adverse events
occur [18]. In contrast, the n-3 HUFA in fish oil (20:5n-3,
22:5n-3, 22:6n-3) competitively and reversibly displace n-6
mediators at multiple steps in the metabolic and patho-
physiological chains of events [8, 18], and supplemental
intakes of n-3 HUFA at doses up to 5 g/day do not raise
safety concerns for adults [22].
Essential n-3 and n-6 nutrients accumulate in tissue
lipids and are released during the following weeks or
months. LA (18:2n-6) accumulates as 10–20 % of the
weight in adipose fat [23], which is often one third of an
individual’s total body mass. Fat is continually released
from adipose into plasma as non-esterified fatty acids
(NEFA), which circulate bound to albumin. The 2- to
4-min half-life of NEFA allows the small transient plasma
pool (500 lmol/L) to transport over 2500 kcal of energy in
24 h. This is near the average daily energy expenditure of
adult Americans. Importantly, 10–20 % of the circulating
NEFA may be n-6 LA, which has a narrow therapeutic
window [18]. Prudent practice would be to ingest n-6 LA at
its lowest effective dose (see Sect. 4.1) and monitor its n-6
HUFA products to avoid adverse conditions.
An efficient elongation–desaturation pathway [18] con-
tinually converts circulating LA (3.4 mM in plasma [24])
into the major n-6 HUFA, arachidonic acid (20:4n-6), plus
20:3n-6, 22:4n-6 and 22:5n-6. It also converts alpha-li-
nolenic acid (ALA; 18:3n-3) into the n-3 HUFA (20:5n-3,
22:5n-3 and 22:6n-3) also present in fish oil. The n-3 and
n-6 HUFA readily esterify into tissue phospholipids [25],
from which accumulated HUFA are released and form
potent eicosanoids [8, 26]. Their competing beneficial and
harmful actions create the environment into which Amer-
icans introduce the n-3 HUFA of supplemental fish oil to
cut CVD risk, and the % n-6 in HUFA can be used to
monitor the intervention’s effectiveness.
3 Balancing Two Timescales in Cardiovascular
Risk
Two processes with vastly different timescales combine to
cause a fatal heart attack: (1) slow, decades-long inflam-
matory damage to the vascular wall; and (2) sudden
formation of platelet aggregates, which stop the flow of
oxygenated blood to the heart or brain. Both inflammation
and thrombosis involve excessive actions of food-based n-6
products of the arachidonic acid cascade, which are
diminished by n-3 nutrients.
3.1 Long-Term Chronic Inflammatory Damage
CVD is a progressive, chronic inflammatory disorder [27],
which begins in adolescence and increases steadily with
age [28]. Autopsy specimens from all American teenagers
studied have had evident vascular damage. The damaged
surface area of the abdominal aorta was near 20 % at
18 years of age, 32 % at 28 years of age and 40 % at
32 years of age. Continual initiation of vascular damage
proceeds unrecognized for decades until the accumulated
damage eventually creates clinical signs and symptoms of
CVD. The steady inflammatory progression results in a
high prevalence of CVD among Americans; nearly 40 % of
40-year-old, 60 % of 60-year-old and 80 % of 80-year-old
have CHD [1]. Successful primary prevention needs to start
in adolescence and prevent repeated exposures to food-
based vascular insults and injuries.
CVD begins when postprandial food energy creates
transient dysfunction in the arterial endothelium, recruiting
and activating monocytes, which differentiate into macro-
phages and progressively form inflammatory plaques [18].
The plaques start to develop in regions of turbulent eddy
flow, where residence times are longer and inflammatory
chemokines, cytokines and adherent cells can accumulate
[29, 30]. These recruit more inflammatory cells, which
further create and amplify chronic inflammatory conditions
and eventually form the foam cells that are characteristic of
atherosclerosis. Increased food energy intake raises circu-
lating levels of cholesterol and phospholipid, and increased
energy expenditure lowers them [31, 32]. This makes cir-
culating cholesterol a biomarker associated with repeated
transient postprandial energy excesses, and the 1984
Cholesterol Consensus Conference report urged vigorous
control of food energy to prevent CVD [33]. That has not
yet occurred.
3.1.1 Transient Energy Excess and Oxidant Stress
The average rate of energy expenditure is important for
understanding energy balance in modern American life-
styles. Many current activities burn only about 200 kcal in
3 h: sleeping, eating, riding in public transport, standing in
line, using computers, reading, watching television or
driving a car [18]. During 3 h after a typical American
restaurant meal of 1327 kcal [34], the liver converts the
extra 1000 kcal into triacylglycerols and cholesterol and
secretes them as very low-density lipoprotein (VLDL).
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Every large meal gives lots of NEFA released from chy-
lomicrons and VLDL by lipoprotein lipase tethered to a
glycoprotein on endothelial cell surfaces [18].
Transient postprandial NEFA act with peroxisomes and
mitochondria to produce reactive oxygen species, which
impair endothelial function [35, 36]. NEFA also activate
protein kinase C, which further increases production of
reactive oxygen species by nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidase. The increase in
oxygen-derived free radicals impairs formation of anti-
thrombotic prostacyclin (PGI), quenches nitric oxide and
suppresses endothelial-mediated dilation [37]. It also oxi-
dizes phospholipids and activates the nuclear factor (NF)-
kB signalling pathway, which induces transcription of the
genes that form inflammatory chemokines and cytokines
and promote more inflammation plus apoptotic death of
endothelial cells, with further recruitment of inflammatory
cells [38, 39]. Three meals per day give 1000 occasions
annually in which transient, reversible local endothelial
dysfunction might convert into a chronic inflammatory
locus. Each instance in which a transient oxidative insult
does not resolve may start a chain of events that eventually
becomes an atherosclerotic plaque.
3.1.2 Preventing Endothelial Dysfunction with Fish Oil
Fish oil supplementation increases nitric oxide availability
and diminishes transient postprandial oxidative stress and
vascular dysfunction [40, 41]. Eating n-3 HUFA maintains
endothelial integrity with increased numbers of endothelial
progenitor cells and reduced numbers of endothelial
microparticles [42]. Improved bioavailability and function
of endothelial progenitor cells [43] may be how marine
diets have protected some ethnic groups from the epidemic
of progressive vascular damage seen in the USA. Fish oil–
enriched diets give a HUFA balance that improves
endothelial progenitor cell function [44] and decreases the
occasional transition to chronic inflammatory
pathophysiology.
Local vascular inflammation is amplified further by the
potent chemotactic n-6 leukotriene B4 (LTB4). It is formed
from the n-6 HUFA arachidonic acid by 5-lipoxygenase
(rather than the cyclooxygenases that form prostanoids)
[8]. The n-6 LTB4 acting with the BLT-1 receptor pro-
motes atherosclerosis by (1) enhancing recruitment, adhe-
sion and activation of inflammatory leukocytes; (2)
providing an amplifier loop of monocyte chemotaxis via
chemokine (C-C motif) ligand 2 (CCL2) production; and
(3) converting monocytes into foam cells through enhanced
expression of CD36 and fatty acid accumulation [45, 46].
When the tissue HUFA balance has more n-3 than n-6, the
100-fold weaker action of the n-3 LTB5 [47] competitively
moderates unwanted n-6 actions. Such moderation seems
evident in the 25-year, longitudinal Seven Countries Study
initiated by Ansel Keys. The biomarker for imbalanced
food energy intake and expenditure—blood cholesterol—
was associated positively with CVD death in Northern
Europe and the USA (where the average % n-6 in HUFA
was near 75–80 %) but not in Japan [48–50] (where the
average % n-6 in HUFA was near 40–50 %).
Dietary habits produce predictably different proportions
of n-3 and n-6 HUFA in tissue phospholipids [12, 51] and
different risks of CVD death [13]. The extent to which the
food energy biomarker, blood cholesterol, correlated with
CVD death was related directly to the extent to which the
pro-inflammatory biomarker, % n-6 in HUFA, exceeded
the less inflammatory % n-3 in HUFA [18, 51]. The added
possible formation of anti-inflammatory, pro-resolving
actions of n-3 HUFA derivatives (resolvins, maresins and
protectins [52]) further indicates a benefit from higher
proportions of n-3 in HUFA. Endothelium with a high %
n-3 in HUFA may recover more readily from transient
postprandial NEFA insults, whereas a high % n-6 in HUFA
may amplify transient insults into chronic inflammatory
injury [8, 17]. Because tissue HUFA proportions pre-
dictably relate to average dietary intakes of 11 different n-3
and n-6 nutrients [50], the HUFA balance is a useful bio-
marker of nutrient intakes and also a valid surrogate for
chronic vascular damage and eventual CVD death. This
biomarker and enhanced endothelial injury from food
energy could serve as valid surrogates for a CVD preven-
tion trial. This aspect is discussed in Sect. 4.2 with regard
to designing an effective dose for fish oil interventions.
3.2 Acute Thrombotic Events
Cardiovascular death results from fatal interactions of an
impaired vascular wall with platelets and clotting proteins.
Decades of inflammatory vascular damage [28] progres-
sively increase the likelihood of some event triggering
activation, adhesion and aggregation of platelets and for-
mation of a thrombus. Thrombosis involves multiple ago-
nists with positive feedback signals causing platelet shape
change and granule secretion, which activates other plate-
lets, promotes wound repair and initiates inflammatory
responses [53]. In healthy people, platelet-mediated throm-
botic processes are balanced by potent anti-thrombotic
agonists released from healthy vascular endothelial cells.
3.2.1 Multiple Amplifier Cascades
Many agonists activate platelets to aggregate: collagen,
fibrinogen, von Willebrand factor, adenosine diphosphate
(ADP), serotonin, thrombin, epinephrine and arachidonic
acid [54]. Their actions are amplified by thromboxane A
(TXA) [55], formed by the arachidonic acid cascade [8].
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Platelet cyclooxygenase converts n-3 and n-6 HUFA into
the hydroperoxide, prostaglandin G (n-3 PGG3 and n-6
PGG2) [8]. PGG is reduced to the hydroxyl form, PGH, and
thromboxane synthase converts PGH into the very unsta-
ble TXA [56]. TXA spontaneously decomposes with a
half-life of 30 s, which limits its action on the selective
TXA receptor, TP. TP action releases calcium (Ca2?) and
ADP [55, 57] and promotes an ‘oxidant burst’, which forms
H2O2 while also activating phospholipase A2-catalysed
release of HUFA from platelet membranes.
The released hydroperoxide activator and HUFA sub-
strate amplify more cyclooxygenase-catalysed formation of
PGG, PGH and TXA, which trigger more aggregation and
release of more activating agents. The need for hydroper-
oxide activation by cyclooxygenase and lipoxygenase
activities to produce more activating hydroperoxides
[57, 58] illustrates the explosive nature of fatty acid oxy-
genase actions [59, 60]. Lowering the local abundance of
hydroperoxide activators by cellular peroxidases slows the
arachidonate cascade and enhances the inhibitory efficacy
of n-3 HUFA and certain anti-inflammatory drugs [61, 62].
Slower formation of hydroperoxide product/activator
(PGG) by n-3 HUFA (20:5n-3) relative to n-6 HUFA
(20:4n-6) [59, 63, 64] makes the formation and action of
n-3 autacoids less intense than those of n-6 autacoids
[8, 26] and more vulnerable to suppression by peroxidases.
Amplified signals during platelet aggregation stimulate
much more PGH2 and TXA2 formation than is needed. As
a result, inhibition of ex vivo serum TXB2 formation must
be virtually complete before thromboxane-dependent
in vivo platelet aggregation is diminished [65].
The PGH formed in vivo by activated platelets can dif-
fuse to adjacent healthy endothelial cells, which have a PGI
synthase that converts PGH into the relatively stable and
potent anti-thrombotic agent PGI [66–68]. Platelet/vascular
wall interactions have pro-thrombotic thromboxane and anti-
thrombotic PGI acting in adjacent cells, and bleeding times
give a crude estimate of the in vivo balance in platelet–
endothelium interactions [65, 69]. The interactions do not
occur in ex vivo measures of platelet function, which are
poor indicators of in vivo dynamics. PGI potently inhibits
platelet aggregation, as it acts through the G-protein coupled
receptor IP, which stimulates formation of cyclic AMP
(cAMP) and suppresses platelet aggregation. PGI synthase is
impaired by oxidants formed during transient postprandial
conditions and vascular inflammation. The progressive
accumulation of inflammatory atherosclerotic plaques
increases the risk of triggering fatal thrombotic events.
3.2.2 Anti-inflammatory Drugs and Fish Oil
Important insight into excessive actions by n-6 essential
fatty acids came with recognition that aspirin inhibits the
cyclooxygenase enzyme [70, 71] in a time-dependent,
concentration-dependent, irreversible manner [72]. Suc-
cessful moderation of the pathophysiology by a large
number of aspirin-like anti-inflammatory drugs [73] con-
firmed that formation of eicosanoids from n-6 arachidonic
acid is an important underlying process in CVD and its
related comorbidities [8, 17]. Aspirin is accepted for
immediate treatment of suspected thrombotic ischaemia,
since it acts within minutes to stop platelet formation of
pro-thrombotic TXA2. However, aspirin has a narrow
therapeutic window before serious adverse events occur, as
it blocks formation of beneficial eicosanoids (e.g. pros-
taglandins protect gastric mucosa, and PGI prevents
thrombosis). As a result, continual use of 325 mg doses of
aspirin is not advised, to prevent the decades-long
inflammatory vascular damage that eventually predisposes
to thrombosis.
Low-dose aspirin (85 mg) has a paradoxical ability to
increase bleeding times, while a 325 mg dose has no sig-
nificant effect [69]. The non-nucleated platelets cannot use
gene transcription and translation to replace the irreversibly
inactivated cyclooxygenase [74, 75]. After a 325 mg dose
of aspirin, it takes several days for megakaryocytes to form
enough new platelets to support thrombus formation. A
careful and insightful review of six large primary preven-
tion trials of aspirin [76] noted that low-dose aspirin
avoided the serious bleeding seen with higher doses, but it
gave no significant reductions in fatal coronary heart dis-
ease (CHD), stroke or vascular death (whereas secondary
prevention trials involving impaired arteries had slightly
fewer of those outcomes in patients allocated to aspirin).
Two subsequent reports [77, 78] described an apparent lack
of CVD risk reduction from primary prevention with low-
dose aspirin.
However, Meade [76] noted that assessment of the
overall benefits of primary prevention with aspirin should
acknowledge reduced mortality from cancers (e.g. breast,
colorectal and prostate cancers) that are promoted by
cyclooxygenase products. Shifting the HUFA balance to
prevent these and other n-6-mediated comorbidities may be
a positive intervention that avoids the narrow therapeutic
windows of aspirin or LA (18:2n-6).
Intervention with n-3 HUFA (20:5n-3) reversibly redu-
ces thromboxane formation and platelet aggregation [79].
The explosive synthetic capacity of platelets, which makes
controlling thrombosis difficult to manage, was evident
when thromboxane formation decreased in most patients
who were treated, but aggregation decreased only when
thromboxane formation was \30 ng/mL [79]. Adding
20:5n-3 directly to platelets did not induce aggregation,
even though some n-3 TXA3 was formed [80]. In contrast,
adding 20:5n-3 to vascular tissue formed the anti-aggre-
gatory prostacyclin PGI3 and shifted the platelet–vascular
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haemodynamic balance, which is important in predicting
CVD risk. Later studies found that the n-3 HUFA 20:5n-3
forms TXA3 at about 10 % of the rate at which the n-6
HUFA 20:4n-6 forms TXA2 [81, 82]. The slower rate of
formation of TXA3, combined with its rapid rate of
decomposition, may leave little active ligand free to act
with the TP receptor and cause thrombosis.
In contrast to the repeated beneficial associations for n-3
HUFA lifetime exposure in cross-national reports [13, 83],
time-limited clinical trials of primary and secondary pre-
vention of CVD have given confusing mixed messages.
Casula et al. [84] assessed 11 randomized, double-blind,
placebo-controlled trials selected from 360 articles and saw
statistically significant protective effects for cardiac death
(RR 0.68), sudden death (RR 0.67) and myocardial
infarction (RR 0.75) but not for all-cause mortality (RR
0.89) and stroke (RR 1.31). The analysis included no
assessment of intake of competing n-6 nutrients or of the
tissue HUFA balance before and after the nutritional
intervention. The biomarker % n-6 in HUFA is able to
measure compliance and the extent of change in the HUFA
balance to better inform interpretations of how an inter-
vention altered risk. It ranged widely (from 25 to 85 % n-6
in HUFA) in cross-national comparisons but likely differed
less in time-limited clinical trials with homogeneous
groups, which gave insufficient attention to creating a
balance in n-3 and n-6 HUFA [17].
Wen et al. [85] evaluated 14 randomized, controlled trials
picked from 3983 records. With no assessment of competing
n-6 nutrient intakes or the tissue HUFA balance before and
after intervention, the investigators concluded that use of n-3
HUFA supplements in CHD patients had no protective
effect on major cardiovascular events. However, use of n-3
HUFA supplements was associated with reduced death from
cardiac causes, sudden cardiac death and death from all
causes. Rizos et al. [86] evaluated 20 studies from 3635
publications (18 using supplements), again with no assess-
ment of the competing n-6 nutrient intakes or of any change
in the tissue HUFA balance. Overall, intakes of 0.53–1.80 g
of n-3 HUFA per day was not associated with lower all-
cause mortality, cardiac death, sudden death, myocardial
infarction or stroke. To better interpret results from ran-
domized clinical trials, future investigators might design
robust alterations of the HUFA balance [17] and gather data
on important biomarkers of dosage and dynamics.
4 Balancing Dose Dynamics and Saturable Sites
4.1 Basic Receptor Dynamics
In the early twentieth century, chemists knew that reaction
rates increased linearly with the concentrations of
reactants. When some enzyme-catalysed rates responded
linearly to enzyme concentration but not to reactant con-
centrations, people realized that catalysts (and receptors)
have hyperbolic saturable dynamics. Catalysed rates (and
receptor responses) follow a non-linear model:
response = Vmax/(1 ? Km/S), where increased amounts of
the substrate (S) increase responses until the maximal
response (Vmax) is approached, when the amounts of S be-
come several-fold greater than the half-maximal concen-
tration (Km). This characteristic hyperbolic saturation must
be recognized when evaluating responses for an active site
or receptor saturated with an agonist. Under this condition,
receptor-mediated processes lack the linear dose–response
behaviour seen with small amounts of a substrate. Such
saturation occurs during platelet aggregation by TXA and
during formation of n-6 HUFA from LA (18:2n-6). The
lack of an observed change with a changing substrate likely
indicates that the system is operating near a maximal
response rather than not acting.
An expanded model describes how a competing ligand
(I) decreases enzyme-catalysed rates or receptor responses:
response = Vmax/(1 ? (Km(1 ? I/Ki))/S). Increased
amounts of an inhibitor (I) increase the apparent mid-
maximal amount (i.e. Km(1 ? I/Ki)) and decrease the
response with a given amount of substrate (especially when
I[[Ki). This occurs continually during conversion of the
competing 18-carbon essential nutrients, 18:2n-6 (LA) and
18:3n-3 (ALA), into corresponding 20-carbon HUFA. The
two nutrients have similar conversion rates and similar Km
values near 0.1 % of food energy (0.1 en%) [18]. However,
a 10-fold greater supply of n-6 than n-3 nutrients in typical
American foods competitively slows conversion of the n-3
nutrient into tissue n-3 HUFA (see blue circle in curve C in
Fig. 3). In contrast, the 0.7 en% n-3 nutrient intake has
little impact on conversion of 6 en% 18:2n-6 nutrient into
its n-6 HUFA (see blue circle in curve B in Fig. 3). The
outcome is near-maximal formation of the tissue n-6
HUFA arachidonic acid (20:4n-6), with a low apparent
ability of the n-3 nutrient to form n-3 HUFA. The low
apparent ability is misunderstood by many people to be a
fixed aspect of ALA action, but it will reverse when more
n-3 than n-6 nutrient is eaten.
Like the metabolic formation of n-3 and n-6 HUFA from
18-carbon precursors, acyltransferase placement of n-3 and
n-6 HUFA into the 2-position of tissue phospholipids also
has competitive dynamics [25]. As a result, the vigorous
supply of n-6 HUFA continually being made from LA
(18:2n-6) raises the apparent mid-maximal amount (i.e.
Km(1 ? I/Ki)) for n-3 HUFA accumulation in membrane
phospholipids. This competition combines with a limited
supply of n-3 HUFA formed from ALA (18:3n-3) to
maintain a high average of 75–80 % n-6 in the HUFA of
Americans [12, 13, 18, 51]. This proportion is lowered by
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eating fewer n-6 nutrients with more n-3 nutrients. The
competition of n-3 and n-6 HUFA for accumulation in
membrane phospholipids needs to be monitored and
reported to ensure that different clinical studies with dif-
ferent HUFA balances are appropriately combined and
interpreted during meta-analyses.
After the 1964 discovery that both n-3 and n-6 HUFA
form potent bioactive derivatives [87], it became evident
that dietary n-3 HUFA could competitively moderate
unwanted events mediated by n-6 HUFA [58, 88, 89]. This
made it useful to understand the quantitative relationship
between average dietary intakes of n-3 and n-6 nutrients
and the HUFA balance in tissues to design effective dietary
interventions to moderate HUFA-based health conditions.
An empirical data-based hyperbolic model successfully
fitted metabolic data for mice, rats and humans [12, 90]. It
also fitted diet–tissue data from nearly 4000 people in 92
subject groups in 34 published studies from 11 different
countries (Strandjord, Lands and Hibbeln 2011; unpub-
lished data).
The quantitative equation was embedded into software
for convenient predictions of the impact that a dietary reg-
imen would have on the tissue HUFA balance [91, 92]. In
addition, an omega 3–6 balance score combines data for 11
n-3 and n-6 nutrients in a food item to make readily visible
the impact that each food item likely has on the health risk
assessment biomarker % n-6 in HUFA [50]. Foods with
positive scores increase the % n-3 in HUFA, and those with
negative scores increase the % n-6 in HUFA [93].
4.2 Narrow Therapeutic Windows Create Problems
The use of anti-thrombotic agents (aspirin, clopidogrel,
dipyridamole, abciximab, heparin, dicoumarol and war-
farin) provides many examples of a narrow therapeutic
window for which the lowest effective dose is advised,
with continual monitoring to avoid adverse events [21].
The need for strong interventions to slow the explosive
amplifying action of n-6 TXA2 during thrombus formation
creates a problem when a low-dose drug is ineffective and
more is excessive [19]. In contrast, fish oil interventions
decrease the proportion of n-6 in the HUFA released during
platelet activation, moderating n-6 actions competitively
without causing major adverse events [22]. In this way, fish
oil widens the therapeutic window for n-6 nutrients [18]
and permits safe long-term interventions.
In the absence of n-3 nutrients, the highly efficient
conversion of dietary n-6 LA into the n-6 HUFA arachi-
donic acid allows LA at only 0.3 en% to maintain about
50 % n-6 in HUFA and prevent signs of essential fatty acid
deficiency [18]. The mid-point in the dose–response curve
was near 0.1 en% [18, 51]. In the absence of dietary n-3
nutrients, intakes above 0.5 en% linoleate maintain near
80 % n-6 in HUFA. Importantly, people with[50 % n-6 in
HUFA are at much greater risk of CVD death than those
with\50 % n-6 in HUFA [12, 13, 51]. In the absence of
dietary n-3 nutrients, eating less LA than the 0.1 en% that
maintains 50 % n-6 in HUFA may cause a deficiency,
whereas eating[0.5 en% increases the risk of many health
conditions mediated by n-6 eicosanoids (Fig. 2). Current
average USA intakes of 6–10 en% LA far exceed the
narrow therapeutic window of around 0.3 en% [18],
forming n-6 HUFA (20:4n-6) continually near maximal
rates and suppressing n-3 HUFA storage. This is the reality
into which we introduce dietary n-3 HUFA.
Successful handling of the competitive dynamics
described above was achieved in a randomized, single-
blind, parallel-group clinical trial, which used two diets
with extensive dietitian counselling. Following a 4-week
baseline period, patients ate (for 12 weeks) a diet with
either much lower n-6 nutrients (L6) or low n-6 plus high
n-3 HUFA (H3-L6) [94, 95]. The HUFA balance for the L6
group shifted only from 77.8 to 74.6 % n-6 in HUFA, as
expected for linoleate intakes far above its mid-maximal
value (see curve B in Fig. 3). In contrast, the H3-L6 group
shifted from 77.1 to 60.9 % n-6 in HUFA, as dietary n-3
HUFA displaced n-6 HUFA. Importantly, the shifted
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Fig. 3 Competing dose-responses in highly unsaturated fatty acid
(HUFA) Formation. This simple model shows the fractional maximal
responses of HUFA formation to dietary intake of precursors. It has a
sensitive linear response to dietary intake of either 18:2n-6 linoleic
acid (LA) or 18:3n-3 alpha-linolenic acid (ALA) alone from 0 to
0.5 % of food energy (0 to 0.5 en%), with a half-maximal response
near 0.1 en% (curve A). In the presence of 0.7 en% ALA, the linear
range of LA action is from 0 to 1.5 en%, with a half-maximal
response when both nutrients are near 0.7 en% (curve B). Intake of
ALA in the presence of 6 en% LA forms n-3 HUFA, with a half-
maximal response near 6 en% ALA (curve C)
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headaches to drop from 9.8 to 8.6 in L6 patients and from
10.2 to 5.6 in H3-L6 patients. Clearly, the lower % n-6 in
HUFA gave biologically important benefits.
5 Planning for Benefits from Fish Oil Intervention
5.1 Treatment Versus Preventing the Need
for Treatment
The n-3 and n-6 HUFA in tissue phospholipids are the
starting point of the arachidonic acid cascade [8], forming
eicosanoids, which act on specific receptors affecting
nearly all cells and tissues of the body. In general, for-
mation and action of n-6 eicosanoids is more vigorous than
that of n-3 eicosanoids [26]. Many unwanted health con-
ditions listed in Fig. 2 involve excessive actions of n-6
eicosanoids [14, 18]. This situation leads to the question of
whether to treat the signs and symptoms of those condi-
tions or to prevent the tissue imbalance that causes the
signs and symptoms. Food choices that increase the pro-
portions of n-3 HUFA (and decrease n-6 HUFA) in tissue
phospholipids can decrease the risk of CVD and many
other conditions made worse by n-6 eicosanoid actions.
The harm from n-6 actions is clearly evident in the greater
unintended CVD deaths from added n-6 LA [5, 96].
The Multiple Risk Factor Intervention Trial (MRFIT) was
a randomized, primary prevention trial focusing on death
from CHD. It involved 28 institutions, 250 investigators and
12,866 men monitored for[7 years [97]. Men aged 35–57
years were randomly assigned either to a special interven-
tion (SI) programme or to their usual healthcare (UC). The
CHD death rates were 17.9 per 1000 in the SI group and
19.3 per 1000 in the UC group, and the total death rates were
41.2 per 1000 (SI) and 40.4 per 1000 (UC). No beneficial
effect on CHD or total mortality came from the multi-factor
intervention [97]. However, the extensive data gave a useful
insight regarding the HUFA balance. Serum phospholipids
from 94 matched cases and controls had a HUFA balance of
78.7 % n-6 in HUFA from cases compared with 76.5 % n-6
in HUFA from controls [98].
Careful food intake data from the 6250 UC men (see
Table I in Ref. [99]), combined with the empirical model
described in Sect. 4.1, give an overall predicted value of
78 % n-6 in HUFA. Quintiles ranked by n-3 HUFA intake
(0.001, 0.004, 0.019, 0.063 and 0.272 en%) [100] had
predicted HUFA balance values of 82.8, 82.4, 80.9, 76.8
and 63.3 % n-6 in HUFA, respectively [13]. Importantly,
the lowest quintile of n-6 in HUFA had 24 deaths com-
pared with 42 deaths in the highest quintile [13]. Similarly,
Cree communities with HUFA balance values near 45 %
n-6 in HUFA had less than half the CVD mortality of
people in Quebec City with values near 75 % n-6 in HUFA
[13]. The 1992 report (see Table VIII in Ref. [99]) also
described the Japanese post-war trend in n-3 and n-6
intakes, which predicted a shifted HUFA balance from
1945 (34 %) to 1965 (46 %) and 1985 (55 %) in compar-
ison with the MRFIT data from the late 1970s (81 %).
These results point towards designing a primary prevention
plan that informs participants of foods they can eat to shift
their HUFA balance towards their desired personal HUFA
balance goal [16, 91, 92]. Two simple, objective metrics in
an individual’s health record [14] document the progress
and success of the plan in giving benefit: (1) the individ-
ual’s previous and current values for the % n-6 in the
HUFA biomarker; and (2) the corresponding annual
healthcare claims for that individual.
5.2 Follow the Money
Expensive, time-consuming CVD clinical trials became
more controversial, and government funding became lim-
ited, after publication of the equivocal results from the
$115 million MRFIT and the $150 million Coronary Pri-
mary Prevention Trial (CPPT) [3]. These findings led to a
watershed in CVD research funding, as Cholesterol Con-
sensus Conference experts urged dietary intervention to
prevent CVD [33], while private sector organizations gained
permission from the US Food and Drug Administration
(FDA) to fund their own trials of their patented drugs (re-
viewed in detail in Sect. 7.2 of Ref. [51]). The NHLBI
director described the change this way: ‘‘Today, if you don’t
call on the private sector, you are a lousy manager’’ [3].
Since then, widespread attention to statin treatments, rather
than attention to diet priorities, have led to an obesity epi-
demic [51]. Treatments with patented drugs provide profit
for a vast biomedical economy, but they are not needed for
healthy people who have effective primary prevention.
Support for developing effective primary prevention that
balances n-3 and n-6 nutrients will likely come from a sector
that profits from preventing the need for treatments.
One special financial aspect of healthcare in the USA is
the role that private corporations play in partnering with
employees to pay for healthcare costs. A high percentage of
large corporations self-fund their insurance for health-related
financial risk. Employers pay for accounting services from
insurance companies to handle day-to-day details, and
‘catastrophic’ insurance may be bought to cover exceptional
risks. Most medical and pharmacy costs are covered jointly
by employers and employees. When healthy employees need
no treatments, corporate funds readily go to other priorities,
such as acquisition of property, salary increases or new
personnel. This makes it profitable to promote primary pre-
vention in the context of a wellness programme that helps
employees be well and free from the need for treatments
[13, 14, 16].
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Occupational medicine experts indicate that corporate
losses from absenteeism and presenteeism are several-fold
greater than those for medical and pharmacy costs [15].
These unrecognized losses add to the documented burden
of $3 trillion for healthcare in the USA [16]. The large
financial incentive in shifting funds to new priorities
whenever employees are healthy could prompt existing
wellness plans to counsel and coach employees about foods
that improve the HUFA balance and lower the risk of CVD
and other n-6-based chronic health conditions. Prescrip-
tions are not needed to make informed food choices that
give healthy HUFA balances. The relevant apps and
information are freely available [92, 93].
Fragments of data indicate that annual healthcare costs
and CVD risk relate similarly to people’s food-based
HUFA balance [14]. When informed food choices shift the
HUFA balance and many employee chronic health condi-
tions are lessened, employers will likely see multiple-fold
returns on their investment in primary prevention of
HUFA-based conditions. Dietary fish oil could be a suc-
cessful supplement in primary preventive interventions of
CVD that balance the intakes of n-3 and n-6 nutrients and
maintain balanced n-3 and n-6 HUFA in tissues.
6 Conclusions
CVD involves decades-long atherogenic inflammatory
damage of vascular endothelium, which predisposes ves-
sels to explosively rapid platelet-mediated thrombotic
actions. Both processes are amplified by positive feedback
signals with n-6 HUFA–based eicosanoids and are mod-
erated by competing n-3 HUFA from fish oil. Interven-
tions that lower the competing n-6 HUFA allow
supplemental n-3 HUFA to be more effective. The bal-
ance of HUFA in blood normally ranges from 25 % n-6
in HUFA to 85 % n-6 in HUFA, and observational studies
show that cardiovascular death rates are lower in popu-
lations that maintain\50 % n-6 in HUFA of blood lipids.
This evidence indicates that balancing n-3 and n-6 HUFA
in tissues with fish oil can be a successful intervention for
the atherogenesis and thrombosis of CVD. The explosive
thrombosis that is activated by impaired vascular
endothelium requires vigorous suppression of many
thrombogenic mediators, and most anti-thrombotic agents
have narrow therapeutic windows that limit their use. Fish
oil interventions could be safe in high enough doses to
shift the HUFA balance significantly and lower platelet
function, especially if competing dietary n-6 nutrients are
kept at levels below 2 en%.
Clinical trials focused on primary prevention of CVD
need to begin before significant vascular damage occurs,
and they require effective dietary intervention with
thousands of people for many years to give statistically
significant reductions in clinical end points. Limited funds
and low interest from the research community have
delayed the designing of effective primary prevention
studies. Lowering the % n-6 in HUFA and the signals from
n-6 HUFA-based eicosanoids that exacerbate many health
conditions gives many benefits, as it lowers the risks of
these comorbidities. As a result, interest in and funding for
robust long-term interventions that lower the HUFA bal-
ance and its health-related financial losses may fit the pri-
orities of USA employers rather than traditional
governmental and pharmaceutical research organizations.
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